Vaxneuvance
Payments companies reported to CMS as associated with Vaxneuvance. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Vaxneuvance, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Vaxneuvance
These are the largest totals companies reported as associated with Vaxneuvance. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Christopher Belcher | Carmel, IN | Pediatric Infectious Diseases | $63,585.14 |
| Mark Blatter | Pittsburgh, PA | Pediatrics | $57,810.66 |
| Laura Scalfano | Plano, TX | Pediatrics | $21,800.04 |
| Inci Yildirim | New Haven, CT | Pediatric Infectious Diseases | $19,499.54 |
| Javeed Siddiqui | Roseville, CA | Infectious Disease | $16,437.81 |
| Francisco Alvarado | Caguas, PR | Infectious Disease | $14,761.68 |
| Marcus Degraw | Detroit, MI | Pediatrics | $13,989.59 |
| Paul Schulz | Louisville, KY | Infectious Disease | $11,821.75 |
| Vanessa Olivo Echavarry | San Juan, PR | Infectious Disease | $8,014.16 |
| Diego Sanz De La Pena | San Juan, PR | Pediatrics | $7,839.01 |
Prescribed Vaxneuvance?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.